Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 2/2012

01-01-2012 | Adis Drug Evaluation

Saxagliptin

A Review of its Use as Combination Therapy in the Management of Type 2 Diabetes Mellitus in the EU

Author: Lily P. H. Yang

Published in: Drugs | Issue 2/2012

Login to get access

Abstract

Saxagliptin (Onglyza™) is a dipeptidyl peptidase 4 inhibitor widely approved for the treatment of type 2 diabetes mellitus. In the EU, saxagliptin is indicated as combination therapy with metformin, a sulfonylurea, a thiazolidinedione, or insulin (with or without metformin) for the treatment of adult patients with type 2 diabetes, including those with mild to severe renal impairment. This article reviews the clinical efficacy and tolerability of add-on saxagliptin therapy in patients with type 2 diabetes, in line with its approved indications in the EU, and summarizes the drug’s pharmacological properties.
The clinical efficacy of saxagliptin 5 mg/day in combination with metformin, glibenclamide (glyburide), a thiazolidinedione, or insulin (with or without metformin) has been demonstrated in several randomized, double-blind, placebo-controlled, multicentre, phase III trials (18–104 weeks in duration) in patients with type 2 diabetes. In these trials, glycosylated haemoglobin (HbA1c) was changed from baseline (primary endpoint) by a greater extent with add-on saxagliptin 5 mg/day (−1.09% to +0.03%) than with comparator regimens (−0.44% to +0.69%). Two other randomized, double-blind trials showed that saxagliptin 5 mg/day as add-on therapy to metformin was noninferior to uptitrated glipizide in terms of lowering HbA1c (−0.74% vs −0.80%) at 52 weeks, or sitagliptin (−0.52% vs −0.62%) at 18 weeks. Saxagliptin 2.5 mg/day as add-on to existing anti-diabetic therapy was also effective for up to 52 weeks in a randomized, double-blind, placebo-controlled, multicentre trial in patients with type 2 diabetes and renal impairment (HbA1c was reduced by 1.08% vs 0.36%; p ≤ 0.007).
Saxagliptin as add-on therapy for up to 4 years was generally well tolerated in clinical trials. Treatment with saxagliptin did not increase the risk of hypoglycaemia or cardiovascular outcomes relative to placebo or active comparators, and was generally weight neutral.
In conclusion, saxagliptin is a useful option as add-on therapy to metformin, a sulfonylurea, a thiazolidinedione, or insulin (with or without metformin) in patients with type 2 diabetes who require combination therapy.
Literature
1.
Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011 Jul 9; 378(9786): 182–97PubMedCrossRef
2.
Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011 Jul 9; 378(9786): 169–81PubMedCrossRef
3.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010 Jan; 87(1): 4–14PubMedCrossRef
4.
Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res Clin Pract 2010 Jan; 87(1): 15–9PubMedCrossRef
5.
6.
Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010 May; 122(3): 71–80PubMedCrossRef
7.
Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control [published erratum appears in EndocrPract 2009 Nov–Dec; 15 (7): 768–70]. Endocr Pract 2009 Sep–Oct; 15(6): 540–59PubMedCrossRef
8.
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 Jan; 32(1): 193–203PubMedCentralPubMedCrossRef
9.
Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011 Mar–Apr; 17 Suppl. 2: 1–53PubMedCrossRef
10.
11.
12.
13.
14.
15.
Gallwitz B. New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. Diabetes Metab Syndr Obes 2010 May 10; 3: 117–24PubMedCentralPubMedCrossRef
16.
Wang A, Dorso C, Kopcho L, et al. Implications of the prolonged dissociation rate of saxagliptin, a highly potent and selective DPP4 inhibitor, on plasma DPP measurements [abstract no. 2088-PO]. Diabetes 2008 Jun; 57 Suppl. 1: A576–7
17.
Patel CG, Li L, Komoroski BJ, et al. No effect of saxagliptin on QTc interval in healthy subjects [abstract no. 2072-PO]. 69th Scientific Sessions of the American Diabetes Association; 2009 Jun 5–9; New Orleans (LA)
18.
Boulton DW, Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects [abstract no. 0606-P plus poster]. 67th Scientific Sessions of the American Diabetes Association; 2007 Jun 22–26; Chicago (IL)
19.
Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011 Jan; 13(1): 7–18PubMedCrossRef
20.
Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005 Jul 28; 48(15): 5025–37PubMedCrossRef
21.
22.
Kirby M, Yu DMT, O’Connor SP, et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2010 Jan; 118(1): 31–41CrossRef
23.
Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011; 71(11): 1441–67PubMedCrossRef
24.
Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009 Aug 4; 25(10): 2401–11PubMedCrossRef
25.
Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial [published erratum appears in Diabetes Obes Metab 2010 May; 12 (5): 462]. Diabetes Obes Metab 2009 Jun; 11(6): 611–22PubMedCrossRef
26.
DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009 Sep; 32(9): 1649–55PubMedCentralPubMedCrossRef
27.
Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial [published erratum appears in Int J Clin Pract 2010 Jan; 64 (2): 277]. Int J Clin Pract 2009 Sep; 63(9): 1395–406PubMedCentralPubMedCrossRef
28.
Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009 Dec; 94(12): 4810–9PubMedCrossRef
29.
Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008 May; 10(5): 376–86PubMedCrossRef
30.
Yang W, Pan CY, Tou C, et al. Efficacy and safety of saxagliptin added to metformin in Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract 2011 Nov; 94(2): 217–24PubMedCrossRef
31.
Göke B, Gallwitz B, Eriksson J, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010 Nov; 64(12): 1619–31PubMedCrossRef
32.
Scheen AJ, Charpentier G, Östgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010 Oct; 26(7): 540–9PubMedCrossRef
33.
34.
Patel CG, Zhang J, Li L, et al. Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects. J Clin Pharmacol 2010 Oct; 50(10): 1211–6PubMedCrossRef
35.
Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011; 50(4): 253–65PubMedCrossRef
36.
Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions [published erratum appears in Clin Pharmacokinet 2011; 50 (1): 74]. Clin Pharmacokinet 2010; 49(9): 573–88PubMedCrossRef
37.
Patel CG, Kornhauser D, Vachharajani N, et al. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Diabetes Obes Metab 2011 Jul; 13(7): 604–14PubMedCrossRef
38.
Patel CG, Li L, Girgis S, et al. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol Adv Appl 2011 Jun; 3: 13–25CrossRef
39.
Upreti VV, Boulton DW, Li L, et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol 2011 Jul; 72(1): 92–102PubMedCentralPubMedCrossRef
40.
Pan CY, Yang W, Tou C, et al. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev. Epub 2011 Nov 12
41.
Pfützner A, Paz-Pacheco E, Allen E, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabestes Obes Metab 2011; 13(6): 567–76CrossRef
42.
Ravichandran S, DeFronzo R, Garber AJ, et al. Once-daily saxagliptin added to metformin is well tolerated and provides sustained glycaemic control over 102 weeks in patients with type 2 diabetes [abstract no. 132]. Diabetologia 2009 Sep; 52 Suppl. 1: S60CrossRef
43.
Göke B, Gallwitz B, Eriksson J, et al. Saxagliptin vs glipizide as add-on therapy to metformin for type 2 diabetes mellitus (T2DM): long-term safety and efficacy [abstract no. 1110-P]. 71st Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego (CA)
44.
Hermans MP, Delibasi T, Farmer I, et al. Effects of saxagliptin added to sub-maximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: results from the PROMPT study [abstract no. 828]. 47th Annual Meeting of the European Association for the Study of Diabetes; 2011 Sep 12–16; Lisbon
45.
Chacra AR, Tan GH, Ravichandran S, et al. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011 Apr; 8(2): 150–9PubMedCrossRef
46.
Hollander PL, Li J, Frederich R, et al. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2011 Apr; 8(2): 125–35PubMedCrossRef
47.
Charbonnel B, Barnett AH, Donovan M, et al. Saxagliptin (SAXA) add-on therapy improves glycemic control in patients (pts) with poorly controlled type 2 diabetes (T2D) on insulin (INS) alone or INS combined with metformin (MET) [abstract no. 1108-P]. 71st Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego (CA)
48.
Barnett AH, Charbonnel B, Li J, et al. Saxagliptin addon therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy [abstract no. 243]. 47th Annual Meeting of the European Association for the Study of Diabetes; 2011 Sep 12–16; Lisbon
49.
Nowicki M, Rychlik I, Haller H, et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011; 13(6): 523–32PubMedCrossRef
50.
Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011 Dec; 65(12): 1230–9PubMedCrossRef
51.
Rosenstock J, Gross JL, Aguilar Salinas CA, et al. Long-term safety and efficacy of saxagliptin after 4-year follow-up of patients with type 2 diabetes [abstract no. 1086-P]. 71st Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego (CA)
52.
Doucet J, Chacra A, Maheux P, et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011 Apr; 27(4): 863–9PubMedCrossRef
53.
Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010 May; 122(3): 16–27PubMedCrossRef
54.
Erhardt W, Bergenheim K, Townsend R, et al. The cost-effectiveness of saxagliptin versus sulfonylurea (SU) in the treatment of type 2 diabetes mellitus (T2DM) in Germany [abstract no. PDB44]. Value Health 2010 Nov; 13(7): A291–2. Plus poster presented at the 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2010 Nov 6–9; PragueCrossRef
55.
Granström O, Bergenheim K, McEwan P, et al. Cost-effectiveness of saxagliptin (Onlyza®) in type 2 diabetes in Sweden. Prim Care Diabetes. Epub 2011 Oct 14
56.
Grzeszczak W, Czupryniak L, Kolasa K, et al. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes Technol Ther. Epub 2011 Nov 8
57.
Hutchings A, Tolley K, Achana F, et al. Cost-effectiveness of saxagliptin compared to sitagliptin for the treatment of patients with type 2 diabetes mellitus (T2DM) [abstract no. PDB39]. Value Health 2011 Nov; 14(7): A478CrossRef
58.
Ramirez de Arellano A, Brosa M, Franch J, et al. Cost-effectiveness analysis of saxagliptin in the treatment of diabetes mellitus type 2 in Spain [abstract no. PDB45]. Value Health 2010 Nov; 13(7): A292CrossRef
59.
Bergenheim K, Williams SA, Bergeson JG, et al. Cost-effectiveness of saxagliptin in type 2 diabetes in the United States [abstract no. 2369-PO]. 71st Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego (CA)
60.
Elgart JF, Caporale JE, Aiello EC, et al. Cost-effectiveness of saxagliptin treatment in three Latin American countries [abstract no. PDB7]. Value Health 2011 Nov; 14(7): A47
61.
Eliaschewitz FG, Asano E, Nita ME, et al. Cost-utility analysis of saxagliptin as an add-on therapy to metformin in type 2 diabetes patients from the Brazilian private health system [abstract no. PDB62]. Value Health 2010 Nov; 13(7): A295CrossRef
62.
Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004 Oct; 47(10): 1747–59PubMedCrossRef
63.
McEwan P, Peters JR, Bergenheim K, et al. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006 Jan; 22(1): 121–9PubMedCrossRef
64.
LaSalle JR. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. Postgrad Med 2010 Jan; 122(1): 144–52PubMedCrossRef
65.
Matthaei S, Bierwirth R, Fritsche A, et al. Pharmacological antihyperglycemia therapy of type 2 diabetes mellitus: update of the evidence-based guidelines of the German Diabetes Association [in German]. Diabetologie 2009; 4: 32–64CrossRef
66.
Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010 Aug; 12(8): 648–58PubMedCrossRef
67.
68.
Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010; 70(16): 2089–112PubMedCrossRef
69.
Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus [published erratum appears in Drugs 2010; 70 (18): 2475]. Drugs 2010; 70(15): 2051–72PubMedCrossRef
70.
Dhillon S. Sitaliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010; 70(4): 489–512PubMedCrossRef
71.
DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009 Apr; 58(4): 773–95PubMedCentralPubMedCrossRef
72.
73.
Fonseca V, Zhu T, Karyekar C, et al. Adding saxagliptin (SAXA) 5 mg is superior to uptitrating metformin extended release (MET XR) in type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control on a stable dose of MET XR 1500mg [abstract no. 1018-P]. 71st Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego (CA)
74.
Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008 Sep 11; 359(11): 1092–5PubMedCrossRef
75.
Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Incarction (SAVOR-TIMI) 53 Study. Am Heart J 2011 Nov; 162(5): 818–25.e6PubMedCrossRef
76.
Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011 Nov; 27 Suppl. 3: 57–64PubMed
77.
Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011 Jul; 141(1): 150–6PubMedCrossRef
Metadata
Title
Saxagliptin
A Review of its Use as Combination Therapy in the Management of Type 2 Diabetes Mellitus in the EU
Author
Lily P. H. Yang
Publication date
01-01-2012
Publisher
Springer International Publishing
Published in
Drugs / Issue 2/2012
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11208160-000000000-00000

Other articles of this Issue 2/2012

Drugs 2/2012 Go to the issue

Erratum

Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer

Erratum

Erratum to Pharmacotherapy for breakthrough cancer pain

Review Article

Current and Potential Pharmacological Treatment Options for Maintenance Therapy in Opioid-Dependent Individuals

Review Article

Are Proton Pump Inhibitors Safe during Pregnancy and Lactation?

Review Article

Pharmacotherapy for Breakthrough Cancer Pain

Adis Drug Evaluation

Tiotropium Bromide Inhalation Powder